ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1323

Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1

Peter C. Taylor1, Yoshiya Tanaka2, Emily Aiello3, Thomas P.A. Debray4, Chris Watson5, Kristina Harris6 and Gerd Burmester7, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Real-world Analytics, Cytel, Toronto, ON, Canada, 4Biostatistics, Galapagos NV, Mechelen, Belgium, 5Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 6Medical Safety, Galapagos NV, Mechelen, Belgium, 7Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Meeting: ACR Convergence 2023

Keywords: clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), Outcome measures, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1308–1344) RA – Treatments Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate (MTX).1 Patients received background MTX and were randomized 3:3:2:3 to FIL 200 mg (FIL200), FIL 100 mg, adalimumab or placebo. This analysis aimed to identify patterns of response trajectory over 12 months in patients from FINCH 1 receiving FIL200.

Methods: Group-based trajectory modeling is a statistical method which groups individuals based on similar patterns of change in an outcome over time.2 A group-based trajectory modeling approach was applied to identify five distinct phenotypic groups in terms of observed clinical disease activity index (CDAI) outcomes (and components) over a 12-month period (Figure). Responders were recorded as either low disease activity (LDA) or remission, defined as CDAI between ≥ 2.9 and ≤ 10, or ≤ 2.8, respectively, at 6 months.

Results: Mean age, the proportion of females and disease duration were similar across all groups. Improvements in efficacy outcome measures were seen for all groups. Baseline (median interquartile range [IQR]) CDAI was highest (worst) in Group 5 (52 [48, 60]), followed by Group 1 (48 [44, 55]). Groups 1 and 3 showed a rapid reduction in CDAI in the first 6 months and sustained response over 12 months. Groups 2, 4 and 5 demonstrated slower response trajectories, with continued improvements in the proportion of CDAI responders between 6 and 12 months; of note, Group 5 constituted 16.8% (80/475) of the total analysis population. Table shows that despite substantial and comparable improvements in CDAI components across all 5 groups over 12 months, Group 5 demonstrated some residual disease activity.

Conclusion: A group-based multivariate trajectory model identified five distinct CDAI disease activity trajectories in patients from FINCH 1 receiving FIL200. Patients in all groups demonstrated either fast and sustained response or slower and continued improvements, with no or low numbers of swollen or tender joints at Month 12. The current analysis suggests that patients who do not achieve CDAI LDA within 6-months may still benefit from treatment continuation and informs a range of expectations for times to clinical response. Future work will assess biomarker profiles that may be used to predict the observed clinical response patterns.

References:
1. Combe B, et al. Ann Rheum Dis 2021;80:848–58
2. Nagin DS, et al. Stat Methods Med Res 2018;27:2015–23

Supporting image 1

Figure. CDAI trajectory in patients from FINCH 1 receiving FIL200

Supporting image 2

Table. Efficacy outcomes from baseline to Month 12 in phenotypic patient groups receiving FIL200: CDAI components


Disclosures: P. Taylor: AbbVie, 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 5, Gilead Sciences, 2, GSK, 2, Janssen, 2, Nordic Pharma, 2, Pfizer Inc, 2, Sanofi, 2, UCB, 2; Y. Tanaka: AbbVie, 6, AstraZeneca, 6, BMS, 6, Boehringer-Ingelheim, 6, Chugai, 5, 6, Eisai, 5, 6, Eli Lilly, 6, Gilead, 6, GSK, 6, Mitsubishi-Tanabe, 5, Pfizer, 6, Taiho, 6, Taisho, 5, 6; E. Aiello: Amgen, 2, Cytel, 3, Galapagos, 2, Genmab, 2, Janssen, 2, Pfizer, 2, UCB, 2; T. Debray: Biogen, 2, Galapagos, 2, Gilead, 2; C. Watson: Galapagos, 3, 11; K. Harris: Galapagos, 3, 11; G. Burmester: AbbVie, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Chugai, 6, Galapagos, 2, 6, Lilly, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6.

To cite this abstract in AMA style:

Taylor P, Tanaka Y, Aiello E, Debray T, Watson C, Harris K, Burmester G. Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/distinct-treatment-responses-in-patients-with-rheumatoid-arthritis-receiving-filgotinib-200-mg-over-12-months-a-post-hoc-analysis-of-finch-1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-treatment-responses-in-patients-with-rheumatoid-arthritis-receiving-filgotinib-200-mg-over-12-months-a-post-hoc-analysis-of-finch-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology